anticancer therapy (Lilly/Millennium)

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug Nameanticancer therapy (Lilly/Millennium)
Drug Alias NameNIP45 (Lilly/Millennium)NIP45
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-4 receptors stimulants
TargetsInterleukin-4 receptors
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A